科倫博泰生物－Ｂ(06990.HK)公布，主要產品A400(EP0031)獲得美國食品藥品監督管理局(FDA)批准進入2期臨床開發。A400是第二代選擇性RET(在轉染過程中重排)抑制劑，對常見的RET基因融合和突變具有廣泛活性。
科倫博泰生物(06990.HK)主要產品EP0031獲FDA批准開發2期試驗
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.